ARMISTICE CAPITAL, LLC

Insider Reports History

Reporting-owner location: New York, NY
Latest reporting-owner signature: ARMISTICE CAPITAL, LLC, Name: /s/ Steven Boyd, Title: Managing Member
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for ARMISTICE CAPITAL, LLC

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Common Stock
Shares / value: 7,223,346
Estimated value: $39,583,936
Report date: 28 Jun 2021
Price: $5.48
Ownership: Direct

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Common Stock
Shares / value: 7,223,346
Estimated value: $39,583,936
Report date: 28 Jun 2021
Price: $5.48
Ownership: Indirect

Form 4 holding 10%+ Owner

EYEGATE PHARMACEUTICALS INC

Security class: Common Stock
Shares / value: 785,000
Estimated value: $3,006,550
Report date: 02 Aug 2021
Price: $3.83
Ownership: Indirect

Form 4 holding Director

AYTU BIOPHARMA, INC

Security class: Common Stock
Shares / value: 1,342,378
Estimated value: $2,508,904
Report date: 29 Mar 2021
Price: $1.87
Ownership: Direct

Form 4 holding Director

AYTU BIOPHARMA, INC

Security class: Common Stock
Shares / value: 1,342,378
Estimated value: $2,508,904
Report date: 29 Mar 2021
Price: $1.87
Ownership: Indirect

Form 4 holding 10%+ Owner

Avalo Therapeutics, Inc.

Security class: Common Stock
Shares / value: 731,458
Estimated value: $379,919
Report date: 27 Jun 2023
Price: $0.5194
Ownership: Indirect

Form 4 holding 10%+ Owner

Avalo Therapeutics, Inc.

Security class: Common Stock
Shares / value: 34,370
Estimated value: $17,852
Report date: 26 Jun 2023
Price: $0.5194
Ownership: Direct

Form 4 holding Director

TENAX THERAPEUTICS, INC.

Security class: Pre-Funded Common Stock Purchase Warrants
Shares / value: 10,596,027
Estimated value
Report date: 18 May 2022
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

TENAX THERAPEUTICS, INC.

Security class: Series C Common Stock Purchase Warrants
Shares / value: 10,596,027
Estimated value
Report date: 18 May 2022
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

TENAX THERAPEUTICS, INC.

Security class: Warrant (right to buy)
Shares / value: 4,773,269
Estimated value
Report date: 18 May 2022
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

TENAX THERAPEUTICS, INC.

Security class: Series B Common Stock Purchase Warrants
Shares / value: 3,175,924
Estimated value
Report date: 18 May 2022
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding Director

TENAX THERAPEUTICS, INC.

Security class: Common Stock Purchase Warrants
Shares / value: 2,072,538
Estimated value
Report date: 18 May 2022
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

EYEGATE PHARMACEUTICALS INC

Security class: Series C Convertible Preferred Stock
Shares / value: 0
Estimated value
Report date: 27 Jul 2021
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Series A Warrants
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Direct
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Series A Warrants
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Indirect
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Series E Warrants
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Direct
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Series E Warrants
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Indirect
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Series G Warrants
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Direct
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Series G Warrants
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Indirect
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Warrant
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Direct
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Lifesciences Inc.

Security class: Warrant
Shares / value: 0
Estimated value
Report date: 28 Jun 2021
Price
Ownership: Indirect
Underlying class: COMMON STOCK
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Direct

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Common Stock
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Indirect

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Series A Warrants
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Series A Warrants
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Series E Warrants
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Series E Warrants
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Series G Warrants
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Series G Warrants
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Warrant
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding 10%+ Owner

ReShape Weightloss Inc.

Security class: Warrant
Shares / value: 0
Estimated value
Report date: 15 Jun 2021
Price
Ownership: Indirect
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by ARMISTICE CAPITAL, LLC

4 AVTX

Avalo Therapeutics, Inc.

Report period: 26 Jun 2023
Transactions: 2
Transaction value: -$2,168,897
Accepted by SEC: 28 Jun 2023, 18:12
Role: 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 03 Feb 2023
Transactions: 3
Transaction value: +$1,319
Accepted by SEC: 09 Feb 2023, 15:32
Role: 10%+ Owner
Next action: Open filing details

4 TENX

TENAX THERAPEUTICS, INC.

Report period: 18 May 2022
Transactions: 12
Transaction value: $0
Accepted by SEC: 19 May 2022, 21:24
Role: Director
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 10 Mar 2022
Transactions: 3
Transaction value: +$151,946
Accepted by SEC: 14 Mar 2022, 17:38
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 03 Mar 2022
Transactions: 3
Transaction value: +$344,132
Accepted by SEC: 07 Mar 2022, 17:09
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 24 Feb 2022
Transactions: 2
Transaction value: +$111,806
Accepted by SEC: 28 Feb 2022, 16:53
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 17 Feb 2022
Transactions: 3
Transaction value: +$231,564
Accepted by SEC: 22 Feb 2022, 17:37
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 18 Jan 2022
Transactions: 3
Transaction value: +$274,486
Accepted by SEC: 20 Jan 2022, 17:14
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 12 Jan 2022
Transactions: 3
Transaction value: +$452,768
Accepted by SEC: 14 Jan 2022, 16:49
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 07 Jan 2022
Transactions: 3
Transaction value: +$642,931
Accepted by SEC: 11 Jan 2022, 17:18
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Avalo Therapeutics, Inc.

Report period: 15 Sep 2021
Transactions: 3
Transaction value: +$12,557,902
Accepted by SEC: 17 Sep 2021, 14:25
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Cerecor Inc.

Report period: 16 Aug 2021
Transactions: 2
Transaction value: +$138,188
Accepted by SEC: 18 Aug 2021, 17:54
Role: Director, 10%+ Owner
Next action: Open filing details

4 AVTX

Cerecor Inc.

Report period: 04 Aug 2021
Transactions: 3
Transaction value: +$408,515
Accepted by SEC: 06 Aug 2021, 15:15
Role: Director, 10%+ Owner
Next action: Open filing details

4 KPRX

EYEGATE PHARMACEUTICALS INC

Report period: 30 Jul 2021
Transactions: 2
Transaction value: -$646,608
Accepted by SEC: 03 Aug 2021, 17:09
Role: 10%+ Owner
Next action: Open filing details

4 KPRX

EYEGATE PHARMACEUTICALS INC

Report period: 27 Jul 2021
Transactions: 9
Transaction value: -$10,454,264
Accepted by SEC: 29 Jul 2021, 19:59
Role: Director, 10%+ Owner
Next action: Open filing details

4 TENX

TENAX THERAPEUTICS, INC.

Report period: 08 Jul 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 09 Jul 2021, 18:03
Role: Director
Next action: Open filing details

4 RSLS

ReShape Lifesciences Inc.

Report period: 28 Jun 2021
Transactions: 24
Transaction value: $0
Accepted by SEC: 29 Jun 2021, 21:44
Role: 10%+ Owner
Next action: Open filing details

4 RSLS

ReShape Lifesciences Inc.

Report period: 16 Jun 2021
Transactions: 12
Transaction value: -$14,230,402
Accepted by SEC: 22 Jun 2021, 08:58
Role: 10%+ Owner
Next action: Open filing details

3 RSLS

ReShape Lifesciences Inc.

Report period: 15 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 22 Jun 2021, 08:49
Role: 10%+ Owner
Next action: Open filing details

4 RSLS

ReShape Weightloss Inc.

Report period: 15 Jun 2021
Transactions: 14
Transaction value: $0
Accepted by SEC: 22 Jun 2021, 08:33
Role: 10%+ Owner
Next action: Open filing details

4 AVTX

Cerecor Inc.

Report period: 14 May 2021
Transactions: 6
Transaction value: +$392,460
Accepted by SEC: 18 May 2021, 18:15
Role: Director, 10%+ Owner
Next action: Open filing details

4 AYTU

AYTU BIOPHARMA, INC

Report period: 20 Mar 2021
Transactions: 4
Transaction value: $0
Accepted by SEC: 10 May 2021, 21:25
Role: Director
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for ARMISTICE CAPITAL, LLC

Insider Reports Filed by ARMISTICE CAPITAL, LLC